First City Capital Management, Inc. Imv Inc. Transaction History

First City Capital Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 21, 2022	BUY	$0.56 - $1.45 $9,184 - $23,780	16,400 Added 3.33%	508,821 $333,000
Q1 2022 May 04, 2022	SELL	$1.07 - $1.5 $3,210 - $4,500	-3,000 Reduced 0.61%	492,421 $694,000
Q4 2021 Feb 07, 2022	SELL	$1.22 - $1.78 $1,220 - $1,780	-1,000 Reduced 0.2%	495,421 $585,000
Q3 2021 Oct 28, 2021	BUY	$1.35 - $2.16 $364,122 - $582,595	269,720 Added 118.98%	496,421 $824,000
Q2 2021 Aug 13, 2021	BUY	$2.12 - $3.24 $344,213 - $526,062	162,365 Added 252.37%	226,701 $374,000
Q1 2021 May 13, 2021	BUY	$2.92 - $4.41 $6,526 - $9,856	2,235 Added 3.6%	64,336 $149,000
Q4 2020 Feb 12, 2021	BUY	$2.9 - $4.4 $34,692 - $52,637	11,963 Added 23.86%	62,101 $262,000
Q3 2020 Nov 16, 2020	BUY	$2.87 - $5.95 $60,663 - $125,765	21,137 Added 72.88%	50,138 $222,000
Q1 2020 May 15, 2020	BUY	$1.4 - $4.92 $62 - $221	45 Added 0.16%	29,001 $50,000
Q4 2019 Feb 10, 2020	BUY	$2.15 - $3.1 $62,255 - $89,763	28,956 New	28,956 $84,000

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of First City Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on First City Capital Management, Inc. with notifications on news.